John Wahren
Hoofd Techniek/Wetenschap/O&O bij Creative Peptides Sweden AB
Profiel
John Wahren was the founder of Cebix, Inc. which was founded in 2008, where he held the title of Director & Chief Scientific Officer from 2010 to 2014.
He is currently employed as an Emeritus Professor-Clinical Physiology at Karolinska Institutet and as Chief Scientific Officer at Creative Peptides Sweden AB.
Dr. Wahren's former position was as a Professor at the University of Lausanne in 1984.
He obtained his doctorate degree from Karolinska Institutet.
Actieve functies van John Wahren
| Bedrijven | Functie | Begin |
|---|---|---|
Creative Peptides Sweden AB
 Creative Peptides Sweden AB Pharmaceuticals: MajorHealth Technology Creative Peptides Sweden AB develops and manufactures drugs. The company discovers and develops biopharmaceutical drugs to treat complications of Type 1 diabetes. It was founded in 1996 and is headquartered in Stockholm, Sweden. | Hoofd Techniek/Wetenschap/O&O | - |
| Karolinska Institutet | Corporate Officer/Principal | 24-06-2009 |
Eerdere bekende functies van John Wahren
| Bedrijven | Functie | Einde |
|---|---|---|
| University of Lausanne | Corporate Officer/Principal | 01-01-1984 |
Cebix, Inc.
 Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | Oprichter | - |
Opleiding van John Wahren
| Karolinska Institutet | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Creative Peptides Sweden AB
Creative Peptides Sweden AB Pharmaceuticals: MajorHealth Technology Creative Peptides Sweden AB develops and manufactures drugs. The company discovers and develops biopharmaceutical drugs to treat complications of Type 1 diabetes. It was founded in 1996 and is headquartered in Stockholm, Sweden. | Health Technology |
Cebix, Inc.
Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | Health Technology |
